Federal Reports

The objective of this audit was to determine whether permit postage and fees, and voided Postage Validation Imprinter (PVI) label refunds were properly issued, supported, and processed at the Topeka, KS, Northpark Station. The PVI is a printing device attached to a point-of-sale terminal that produces a postage label for payment of postage and fees.

The objective of this audit was to determine whether stamps and meter revenue refunds were properly issued, supported, and processed at the Bellmawr, NJ, Main Window. The OIG’s data analytics identified that Bellmawr Main Window had a 128 percent increase in dollars for stamp and meter revenue refunds from April 1 to September 30, 2017, compared to the same period in fiscal year 2016. Of the $72,593 in stamp and meter revenue refunds during the period, the unit recorded $56,335 in Refund Spoiled/Unused Customer Meter Strips and $8,046 in Refund Stamps and Fees.

To listen to a short podcast relating to this report, click the link below.

The Office of the Inspector General conducted an evaluation of Lagoon Creek Combustion Turbine Plant (LCCT) to identify strengths and risks that could impact LCCT’s organizational effectiveness. Our evaluation identified strengths related to (1) teamwork and (2) organizational alignment. However, we also identified issues that could pose risks to LCCT’s effectiveness and its continued ability to meet its responsibilities. These issues related to (1) low morale caused by a lack of accountability and (2) perceptions of unethical behavior.

Our objective was to identify opportunities to improve Surface Visibility (SV) scan compliance at Postal Service processing and distribution centers (P&DCs) in the Capital Metro Area and summarize our prior Western Area SV scanning audit work. This is our second and final report examining SV scanning compliance. We selected the Capital Metro Area for this audit because from fiscal year (FY) 2015, Quarter (Q) 4, to FY 2017, Q4, its average scan compliance rate was about 82 percent, the lowest in the nation. We selected two high-performing sites and two low-performing sites based on their FY 2017 scan compliance, as of July 21, 2017, to identify best practices.

The Indian Health Service's (IHS) travel card program, under which IHS employees are to use Government charge cards for nearly all payments of expenses related to official Government travel, did not always comply with Federal requirements and IHS's own policy. We identified 16 transactions (out of the 151 sampled transactions we tested) that did not comply with Federal requirements and IHS policy regarding proper travel card use. These errors occurred because, although IHS had controls in place to educate cardholders on the requirements for the use of the travel card, the controls did not always prevent misuse of the travel card. Additionally, whereas IHS had controls in place to monitor cardholders, those controls did not always identify noncompliance.

The Centers for Medicare & Medicaid Services (CMS) had policies and procedures in place that were generally effective in ensuring that capitation payments to Medicare Advantage organizations' prescription drug plans and stand-alone prescription drug plans (collectively referred to as "sponsors") for Medicare Part D coverage were not made on behalf of deceased beneficiaries after the individuals' dates of death. These policies and procedures generally ensured that CMS did not make improper capitation payments on behalf of deceased beneficiaries when its data systems indicated at the time of a monthly capitation payment that the beneficiaries in question had died.

The VA Office of Inspector General (OIG) initiated and conducted a study to assess whether VA providers established androgen deficiency (lower levels of male sex hormones, particularly testosterone, than is needed for health) prior to initiating testosterone therapy and the extent VA providers performed follow-up evaluation after initiating the therapy, in accordance with the 2010 Endocrine Society Clinical Practice Guidelines and current VA criteria for use. The OIG found that VA providers generally did not follow Endocrine Society Clinical Practice Guidelines and current VA criteria for use when initiating patients with testosterone replacement therapy or following up with patients within 3–6 months after therapy initiation. VA providers largely did not document clinically significant signs and symptoms consistent with androgen deficiency before initiating therapy or before performing biochemical confirmatory testosterone level tests. This suggests VA providers might have used testosterone tests to screen for, rather than to confirm, androgen deficiency. In addition, VA providers generally did not perform both follicle-stimulating hormone and luteinizing hormone tests to distinguish between primary and secondary androgen deficiency before initiating testosterone replacement therapy. VA providers did not document a discussion of the risks and benefits of testosterone replacement therapy with approximately two out of three patients before therapy initiation. After testosterone replacement therapy initiation, VA providers did not conduct follow-up evaluation within 3–6 months for about two out of three patients before continuing the therapy. The OIG made seven recommendations to the Under Secretary for Health to ensure that providers are in alignment with Veterans Health Administration current guidance related to the initiation and maintenance of testosterone replacement therapy.